continuous combined oral HRT containing 1 mg 17b-estradiol and 0.5 mgnorethisterone acetate (n¼39), whereas the second group received sequen-tial HRT containing estradiol alone (4 mg) given twice a week on days1-14 and estradiol (10 mg) plus norethisterone acetate (30 mg) given twicea week on days 15-28 (n¼37). Twenty patients in the oral HRT group and19 patients in the transdermal HRT group completed the study. Circulatinglevels of MCP-1 were assessed before and after the treatment in allpatients.

RESULTS: There were no statistically significant differences between thebaseline characteristics of the two groups. There were no statistically signif-icant differences between the mean serum MCP-1 levels in oral and trans-dermal HRT groups prior to the study (150.1�12.8 vs. 145.2�11.6 pg/ml;P¼.219). The mean MCP-1 levels did not change after 6 months of HRTuse in both oral HRT group (150.1�12.8 vs. 153.6�12.5 pg/ml; P¼.192)and transdermal HRT group (145.2�11.6 vs. 146.1�15.1 pg/ml; P¼.419)when compared to baseline MCP-1 levels.

Effects of oral and transdermal HRT on MCP-1 levels, after 6 months of

treatment

Baseline 6 months P value

F

ERTILITY & STERILITY�

Oral HRT (pg/ml) (n¼20)

150.1�12.8 153.6�12.5 .192 Transdermal HRT (pg/ml) (n¼19) 145.2�11.6 146.1�15.1 .419

HRT; hormone replacement therapy, MCP-1; monocyte chemoattractant pro-tein-1.Moreover there was no significant difference in MCP-1 serum levels after 6months HRT use between the groups.

CONCLUSION: Both oral continuous and sequential transdermal HRTsdo not affect MCP-1 levels significantly, which is a significant marker forendothelial damage, in young women at early postmenopausal period.

P-3 Tuesday, October 15, 2013

EFFECTOF LOW LEVEL GALLIUM ARSENID DIODE LASERONBONE DENSITY. M. A. A. El-Nouri. Medical Laser, Cairo Univ, Cairo,Egypt.

OBJECTIVE: The aim of the study was to assess and evaluate the effect oflow-level laser irradiation on the bone mineral density in postmenopausalwomen.

DESIGN: Prospective clinical study.MATERIALS AND METHODS: Low level Gallium Arsenid Diode laser

(wavelength at 904nm) at fluence of 30J/sq cm, pulsed wave was used 11 fe-male subjects (mean age� standard deviation, 57 years� 5). A semi station-ary treatment technique (treating point after point) was used over the ultradistal ends of the left radius and ulna. The course consisted of 9 sessions(3 per week), each sessions lasted for 30 minutes.

Outcome Measures: BMD (in grams per square centimeter) wasmeasured with dual energy absorptiometry in the ultra-distal ulna andradius. Measurement of BMD was performed, using dual energy X-ray ab-sorptiometry (DEXA), in the as a marker of biostimulatory effect. Subjec-tive evaluation of therapy was observed using visual analogue scales forpain at rest and movements and assessment of muscle strength, range ofmotion and activities of daily living were documented before treatmentand 1 and 3 months after.

RESULTS: Ultra-distal Ulna and Radius BMD increased with Low po-wer laser biostimulation for 3 weeks by (7.8, and 11.2%) from baselinevs 1.2, and 9.4% for the the contol group of the study. The ultradistalforearm (both radius and ulna) BMD increased in the study group by8.7%. while the control group increased only by 3.3%. Differences inlevels of the BMD were found to be significant comparing irradiatedand non-irradiated groups. There was no significant difference in thepain score, strength of muscles, and range of wrist movement or dailyactivities between the study and control group, before and after treat-ment.

CONCLUSION: Low level Gallium Arsenid Diode laser bio-stimulation increases the BMD in postmenopausal women However Ithas no effect on the pain, range of movements, muscle strength or dailyactivities.

Supported by: Low level Laser irradiation, Osteoporosis.

P-4 Tuesday, October 15, 2013

FSHR POLYMORPHISMS ARE ASSOCIATED WITH PREMA-TURE OVARIAN INSUFFICIENCY DEVELO-PMENT. E. B. Cordts, M. C. Santos, A. A. Santos, F. A. Mafra,D. M. Christofolini. Genetics and Human Reproduction, FMABC, SantoAndre, Sao Paulo, Brazil.

OBJECTIVE: To evaluate the incidence of polymorphisms Asn680Ser(rs6166) and Ala307Thr (rs6165) of the FSHR gene and the occurrence ofchromosomal abnormalities in woman with Premature Ovarian Insufficiency(POI) and in a control group and correlate the genetic and clinical findings.DESIGN: Case control study.MATERIALS AND METHODS: A group of 103 infertile and patients

with POI was selected trough clinical history and serum levels of the hor-mone FSH.The control group included 101 women with no familial historyof POI and normal age of menopause.The genotyping of polymorphismsAsn680Ser (rs6166) and Ala307Thr (rs6165) of the FSHR gene was per-formed in both groups using TaqMan by PCR real time. Cytogenetic analysiswas performed only in the group of patients with POI. 40 methaphases wereevaluated through G banding technique.RESULTS: The karyotype analysis performed in patients POI showed that

98.05% (101/103) presented normal karyotype 46,XX, 1.95% (2/103) showedand increased heterochromatin region in the 9 and 16 chromosomes(46,XX,9qh+;46,XX,16qh+) both considered normal variations in the popula-tion.The genotyping for polymorphisms Ala307Thr demonstrated a statisti-cally significant difference between the allele Ala of the polymorphismAla307Thr, and a p value of 0.035, comparing the POI group with the controlgroup.The analysis ofAsn680Ser polymorphism incidence inpatients and con-trol group showed a non significant difference between them (p¼0.094). Theaverage levels of FSH hormone in POI patients in this study was 57.8mUI/mL.CONCLUSION: We concluded that most patients with POI and no other

phenotypical alteration have normal karyotype, and they do not suspect ofPOI untill testing fertility. Also, we observed that the polymorphic alleleAla from Ala307Thr polymorphism showed statistically significant differ-ence between patients with POI and control group, being more present in pa-tients with POI, suggesting an important rule of FSHr in the regulation offolliculogenesis.Supported by: CNPq for Monise de Castro Santos Scholarship.

P-5 Tuesday, October 15, 2013

ABSTRACT WITHDRAWN

P-6 Tuesday, October 15, 2013

EFFECTS OF TIBOLONE ON SERUM CALCIUM AND 25-HY-DROXY VITAMIN D3 LEVELS ANDHEALTH RELATEDQUALITYOF LIFE (HRQOL) IN POSTMENOPAUSAL (SURGICAL)WOMEN. S. M. Bhattacharya,a,b M. Ghosh.c aObstetrics & Gynecology,S.C.DAS Memorial Medical & Research Center, Kolkata, West Bengal,India; bObstetrics & Gynecology, KPCMedical College, Kolkata, West Ben-gal, India; cPharmacology, Murshidabad Medical College, Murshidabad,West Bengal, India.

OBJECTIVE: There are growing evidences that vitamin D3 sufficiency isrequired for optimal health. Objective is to study the effects of 6 months oftreatment with Tibolone, as hormone replacement therapy (HRT) on BMI(body mass index), serum calcium and 25-hydroxy vitamin D3 levels, Healthrelated quality of life (HRQOL) in postmenopausal (surgically) women andthe relationship between different studied parameters.DESIGN: Prospective interventional study.MATERIALS AND METHODS: Study was done in Kolkata, India be-

tween July, 2012 and March, 2013. Informed written consent and Ethicalapproval were obtained. A sample size of 37 patients was found to have80% power at 5% level of significance to detect a difference of 2.5ng/mlin vitamin D3 level with SD (standard deviation) 6 and a difference of 2points in MRS score (SD 5). 40 patients after surgical menopause with dis-tressing menopausal symptoms were treated with Tab. Tibolone (2.5mgdaily) for 6 months. Parameters studied in each case at baseline and after 6months were- BMI (kg/M2), serum calcium (mg %) and 25 hydroxy vitaminD3 (ng/ml) levels.Each woman scored herself the Menopause Rating Scale(MRS) at the two points of study to assess HRQOL.

S149